Major Histocompatibility Complex-presented tumor-specific neoantigen (TSNA)

Major Histocompatibility Complex (MHC)-presented tumor-specific neoantigens are novel peptides derived from somatic mutations within a tumor that are not present in the normal human genome (Source: National Cancer Institute). These mutations, which include single nucleotide variants, insertions, deletions, and frameshifts, result in the production of "non-self" proteins that are processed and displayed on the cell surface by MHC molecules (Source: Nature Reviews Cancer). Because these neoantigens are absent from healthy tissues, they are highly immunogenic and bypass central thymic tolerance, making them ideal targets for precision immunotherapy (Source: PubMed, PMID: 28831148). Therapeutic strategies targeting these neoantigens include personalized cancer vaccines (mRNA, DNA, or peptide-based) and adoptive T-cell therapies using TCR-engineered cells (Source: Journal of Hematology & Oncology). These interventions aim to stimulate or provide a robust T-cell response specifically against the tumor, minimizing off-target toxicity. However, the high degree of patient-specific variability and the potential for tumor antigen loss remain significant challenges in the clinical application of neoantigen-based therapies (Source: Frontiers in Immunology).

Other names

Tumor neoantigenNeoepitopeMutation-derived antigenMHC-restricted neoantigenTumor-specific antigen (TSA)

Induction of de novo T-cell responses or expansion of existing neoantigen-specific T-cells through vaccination or adoptive cell transfer, leading to targeted lysis of tumor cells expressing the specific peptide-MHC complex.